View post: BMW’s Last Roadster Just Left The Building GLP-3s are investigational, potent weight-loss drugs targeting multiple hormone receptors. Side effects can be strong; medical supervision is ...

GLP-1 therapies continue to reshape chronic disease treatment, triggering regulatory updates, new clinical findings and intensifying competition across the pharmaceutical market. On Jan. 13, the FDA ...

Obesity affects more than bodies. It causes stigma, affects relationships, and can lead to health complications. Losing weight is not easy, but with the advent of new medications on the horizon, there ...

Significantly lower AMD risk compared with other agents in cohort study ...

People searching for an affordable way to lose weight with a GLP-1 drug may come across products marketed as “GLP-1 patches” online. They’re advertised as helping to reduce cravings, control appetite ...

McKesson reported 15% topline growth and 12.2% adjusted EPS growth in their recent earnings report. The company's GLP-1 medications have shown impressive growth, contributing 60% to year-over-year ...

GLP-1 receptor agonists improve outcomes in patients with coronary plaque and post-STEMI, reducing adverse cardiovascular events and hospitalizations. Patients using GLP-1s show higher event-free ...

GLP-1 receptor agonist use remains low in people with multiple sclerosis despite high eligibility rates for diabetes and obesity indications.